Bonesupport Holding AB Delivers High-Growth Earnings Call

BONESUPPORT HOLDING AB ((SE:BONEX)) has held its Q2 earnings call. Read on for the main highlights of the call.

Bonesupport Holding AB’s latest earnings call painted a picture of a company firmly in growth mode, combining strong top-line expansion with scalable profitability. Management acknowledged some short-term headwinds, but emphasized that robust U.S. traction, high margins and solid cash generation are driving a compelling investment case despite regulatory and operational uncertainties.

Strong Revenue Growth

Net sales in Q2 2026 reached SEK 356 million, up 25% year on year in reported terms and 30% at constant exchange rates. Management stressed that the FX‑adjusted figure better reflects underlying momentum, with growth powered mainly by the U.S. market and reinforced by solid demand across Europe and the rest of the world.

Robust Adjusted Profitability

Bonesupport posted an adjusted operating result of SEK 104.1 million, corresponding to a healthy 29% adjusted operating margin. The reported operating profit of SEK 90 million was lower due to long‑term incentive costs, but the company highlighted that underlying profitability remains strong and continues to scale with revenue.

Solid Cash Generation and Liquidity

Operating cash flow came in at SEK 67 million for the quarter, supporting continued investment and shareholder returns. Even after executing an SEK 83 million share buyback, Bonesupport closed Q2 with a solid cash position of SEK 434 million, underscoring balance sheet flexibility for future growth initiatives.

Strong U.S. Traction

U.S. sales rose to SEK 295 million, delivering about 31% growth at constant exchange rates versus Q2 2025. The U.S. contribution increased by $35.8 million to $140.2 million, confirming that the company’s largest market is still in an acceleration phase and remains the key driver of overall performance.

Antibiotic-Eluting CERAMENT Growth

Antibiotic‑eluting CERAMENT products continued to outperform, growing about 40% over the last twelve months at constant exchange rates. CERAMENT G in particular is showing strong launch momentum in the U.S., signaling rising adoption of infection‑focused bone void solutions among surgeons.

Regulatory and Reimbursement Progress

The De Novo regulatory process for CERAMENT V is advancing as planned, with the company submitting responses and awaiting feedback. In parallel, U.S. authorities have proposed improved reimbursement and more precise billing codes for CERAMENT G, which management views as an important structural tailwind if ultimately implemented.

Europe and Rest of World Momentum

EUROW sales reached SEK 61 million, marking 26% growth at constant exchange rates and broad‑based improvements across direct, hybrid and distributor setups. Management also pointed to stabilization in Germany, suggesting that prior volatility in this key European market is easing.

Operational Scalability and Outlook

The quarter reinforced Bonesupport’s scalable business model, with strong margins and cash flows supporting future expansion. Based on the Q2 run rate and a healthy commercial pipeline, management updated and reiterated expectations for full‑year sales growth in the mid‑30s at constant exchange rates.

Temporary Usage Restrictions in U.S. Accounts

A small group of large U.S. hospitals introduced temporary usage controls, such as pre‑approval and stop‑go regimes, which modestly dampened CERAMENT G growth. Management said these restrictions are limited in scope but can be meaningful for reported numbers, while emphasizing that underlying demand remains intact.

Currency Headwinds

Movements in foreign exchange continued to cloud the optics of reported growth, particularly the weaker Swedish krona against the U.S. dollar. As a result, the company reported 25% growth instead of the 30% constant‑currency figure, a gap management urged investors to keep in mind when assessing performance.

Gross Margin Headwinds

Gross margin stayed exceptionally high at 93.8%, but declined slightly versus the prior period due to specific factors. These included a SEK 2.7 million inventory write‑down and ongoing U.S. tariffs, which had a SEK 1.5 million impact compared with last year, though margins remain a clear competitive strength.

Higher Commercial and Incentive Costs

Selling and marketing expenses rose to SEK 135.3 million from SEK 117.8 million, reflecting increased sales commissions and fees of SEK 94.5 million. Long‑term incentive program costs nearly doubled to SEK 14.5 million, reducing reported operating profit relative to adjusted results but supporting commercial expansion and talent retention.

Uncertainty Around Regulatory and Publication Timelines

Management cautioned that several potential catalysts remain outside their control and therefore outside formal guidance. These include the outcome of the CERAMENT V De Novo review, the finalization of reimbursement proposals and the timing of key clinical study publications, all of which could add upside but carry inherent uncertainty.

Spine Segment Still Early Stage

The CERAMENT BVF spine launch is at an early phase and currently contributes only modest sales. Broader spine adoption is expected to depend on additional clinical data, and the antibiotic‑eluting spine indication is seen as a longer‑term opportunity rather than a material driver for the current year.

Regional Operational Challenges

Management flagged geopolitical volatility in the Middle East as a short‑term challenge, affecting local presence and logistics. They also noted that part of EUROW’s strong growth reflects a relatively soft comparison base from Q2 2025, suggesting investors should adjust expectations for normalization over time.

Cash Conversion Below Historical Average

Quarterly cash conversion stood at 67%, below the average of 79% reported since Q3 2024, highlighting some variability in cash efficiency. While not alarming, this metric will be watched by investors as the company balances growth investments, incentives and buybacks against ongoing cash generation.

Forward-Looking Guidance and Outlook

Management reiterated full‑year 2026 guidance for sales growth of 33–36% at constant exchange rates, supported by 31% CER growth in the first half. They highlighted strong margins, cash flows and product momentum, while framing regulatory and reimbursement developments as potential upside that has not been built into current forecasts.

Bonesupport’s earnings call left the impression of a fast‑growing medtech company successfully scaling its business while managing manageable headwinds. For investors, the combination of high growth, strong margins and a solid balance sheet, augmented by potential regulatory and reimbursement catalysts, makes the story one to watch in the orthopedic and infection management space.